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ABSTRACT
Membrane fusion plays a key role in many biological
processes including vesicle trafficking, synaptic
transmission, fertilization or cell entry of enveloped
viruses. As a common feature the fusion process is
mediatedbydistinctmembraneproteins.Wedescribe
here ‘Fusoselect’, a universal procedure allowing the
identification and engineering of molecular determi-
nants for cell–cell fusion-activity by directed evolu-
tion. The system couples cell–cell fusion with the
release of retroviral particles, but can principally be
applied to membrane proteins of non-viral origin as
well. As a model system, we chose a g-retroviral
envelope protein, which naturally becomes fusion-
active through proteolytic processing by the viral
protease. The selection process evolved variants
that, in contrast to the parental protein, mediated
cell–cell fusion in absence of the viral protease.
Detailed analysis of the variants revealed molecular
determinants for fusion competence in the cyto-
plasmic tail (CT) of retroviral Env proteins and
demonstrated the power of Fusoselect.
INTRODUCTION
Nature has evolved a variety of cellular events that are based
on membrane fusion. These include vesicle–cell fusion, virus–
cell fusion and cell-to-cell fusion such as in synaptic trans-
mission, viral cell entry and fertilization, respectively. All
these processes differ not only in their intra or extracellular
environment, but also in the involved molecules and the time
span required for the fusion of the two separate membranes
(1). However, the molecular events underlying membrane
fusion occur in a consensus manner including two
membrane-inserted moieties on opposed membranes, brought
into close proximity through the formation of a stable helical
bundle (2,3). According to the nomenclature originally used to
specify compartments in vesicle trafﬁcking we will refer to
these moieties as fusion donor proteins (proteins or protein
complexes harboring a hydrophobic fusion peptide) and fusion
acceptor proteins (proteins or protein complexes that mediate
comprehensive conformational changes of the fusion donor
protein upon binding) (1,4). Once the membranes are brought
into close proximity by the fusion donor and acceptor proteins,
mixing of the proximal membrane leaﬂets (hemifusion)
occurs. Subsequently, the membrane distal leaﬂets interact
resulting in a rapidly expanding fusion pore.
While membrane fusion during vesicular trafﬁcking
involves supra-molecular complexes (SNARE protein family)
instead of single fusion donor and acceptor proteins, some
viruses have evolved envelope (Env) proteins facilitating
this process without any accessory factors (5,6). In case of
orthomyxoviruses and retroviruses the fusion machinery has
been particularly well characterized and consists of the viral
Env protein (fusion donor) on the virus membrane and a single
virus receptor molecule (fusion acceptor) on the cellular mem-
brane (7). In both cases, the envelope proteins are synthesized
as meta-stable fusion-incompetent precursor molecules. Sub-
sequently, fusion-activity is triggered either by low pH (endo-
cytosis of virus particles) or, in case of retroviruses, by
receptor contact (8).
Most retroviral Env proteins consist of two non-covalently
linked protein domains, the surface unit (SU) and the trans-
membrane protein (TM), which are expressed as a single
precursor polyprotein that is cleaved by a cellular protease
in the Golgi. Env proteins of g-retroviruses, like the murine
leukemia virus (MLV) or the gibbon ape leukemia virus
(GaLV), contain a further regulatory element. This so-
called R peptide, the membrane distal domain of the cyto-
plasmic tail (CT) of the TM protein, inhibits the membrane
*To whom correspondence should be addressed. Tel: ++49 6103 77 4011; Fax: ++49 6103 771255; Email: bucch@pei.de
Present address:
Christoph Merten, ISIS—Bidogie chimique, 670 83 Strasbourg, France.
  The Author 2006. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Nucleic Acids Research, 2006, Vol. 34, No. 5 e41
doi:10.1093/nar/gkl053fusion-activity, thus preventing cytotoxic effects within the
producer cell (9). Accordingly, it is cleaved off by the viral
protease during particle budding thus giving rise to the
fusion-active form of the Env protein. Genetic truncation of
the R peptide hence results in efﬁcient syncytia formation of
cells expressing such Env variants.
Given the broad impact of membrane fusion on different
biological processes thereisgreatinterest inthe engineering of
fusion proteins in order to improve or alter their functions and
to understand the structure/function relationships of these
molecules. Here we used the GaLV Env protein to set up a
system thatallowsthe identiﬁcation ofmolecular determinants
mediating cell–cell fusion-activity by directed evolution.
During selection highly fusogenic Env variants accumulated
revealing different sequence motifs that achieve fusion
competence.
MATERIALS AND METHODS
Cell lines
HEK-293T and NIH-3T3 cells were obtained from the
American Type Culture Collection. Phoenix-Eco cells
(www.stanford.edu/group/nolan) were kindly provided by
Stefan Stein (Georg-Speyer-Haus, Frankfurt, Germany). All
cells were maintained in high glucose (4.5 g/l) DMEM (Gibco,
Eggenstein, Germany) supplemented with 10% fetal calf
serum (FCS; Biochrom, Berlin, Germany), benzylpenicillin
(60 mg/ml) and streptomycin (100 mg/ml) at 37 Ci na n
atmosphere of 5% CO2.
Envelope expression constructs
All plasmids were ampliﬁed in Escherichia coli Top F10 and
GM2163 strains. The MLV-packagable vector pMSCV-NEO
has been described previously (10), and a similar construct
with modiﬁed restriction sites was purchased from Clontech
(Palo Alto, USA) and is referred to as pMSCV-Clontech-Neo.
The BstEII site in pMSCV-Neo was deleted by BstEII restric-
tion, Klenow ﬁll in and religation. The resulting plasmid was
then used to insert an EcoRI-digested PCR fragment encoding
the HA-tagged GaLV Env protein (11) which was ampliﬁed
using the following primers: GaLV-HA-EcoRI(+), 50-CTTA-
GAATTCATGGTATTGCTGCCTGGGTC-30, and GaLV-
HA-EcoRI( ), 50-TCATGAATTCTTACAGAATTTTAAC-
CGCGGATATCC-30. The resulting plasmid pMSCV-
GaLV-HA was used as a parental plasmid to generate the
GaLV envelope library encoding construct pMSCV-GaLV-
X3 and the control vector pMSCV-GaLV-DR by introduction
of double stranded oligonucleotides via SacII/BstEII. These
were generated in a Klenow ﬁll in reaction using forward
primers GaLV-X3(+), 50-GATATCCGCGGTT(G/C/A)NN
(G/C/A)NNCTGTGATAA(G/C/A)NNCAGAAATATCAGG-
CCCTAGAGAACGAAGGTAACCTTT-30 or GaLV-DR(+),
50-GATATCCGCGGTTAAAATTCTGTGATAAAGACAG-
AAATATCAGGCCCTAGAGAACGAAGGTAACCTTT-30
and the reverse primer GaLV-X( ), 50-GTTACCTTCGT-
TCTCTAGAGC-30. After digestion of pMSCV-GaLV-X3
with EcoRI, a diversiﬁed GaLV-HA envelope encoding frag-
ment was obtained which was subsequently inserted into
pMSCV-Clontech-NEO resulting in the bicistronic vector
pMSCV-GaLV-X3-NEO. Ligation and cloning conditions
for the libraries were described previously with the exception
that ElectroTen-Blue bacterial cells were used in 0.1 cm
cuvettes at 1.7 kV, 200 W and 25 mF (12). For both libraries,
 1 · 10
6 independent bacterial clones were obtained. In the-
ory, each library encoded 4.1 · 10
3 different variants, which
were thus well covered by the number of clones obtained.
Sequence analysis of single clones conﬁrmed diverse
sequences with no obvious bias (data not shown). After plat-
ing, cells were scraped off, resuspended and subsequently
expanded in LB medium for puriﬁcation of the plasmid DNA.
Generation of retroviral vectors and target
cell transduction
Twenty four hours prior to transfection 3 · 10
7 Phoenix-Eco
cells were seeded into T175 culture ﬂasks. Transfection was
performed using 45 mg of the respective MLV-packagable
transfer vector and Lipofectamine Plus (Gibco, Eggenstein,
Germany) according to the manufacturer’s instructions. Two
days post transfection the supernatant was collected and ﬁl-
trated through a 0.45 mm ﬁlter. Subsequently, the supernatant
was incubated with NIH-3T3 target cells for 2 h in presence
of 8 mg/ml polybrene.
Library selection
Prior to selection, retroviral vectors having the library pack-
aged were used to transduce 5 · 10
6 NIH-3T3 cells. One day
post transduction 4·10
6 of these cells were mixed with the
same amount of Phoenix-Eco cells and seeded on to the bot-
tom of a transwell chamber (Corning, Schiphol-Rijkand, The
Netherlands). Simultaneously, a permeable membrane coated
with 3 · 10
6 NIH-3T3 cells was inserted into the chamber and
incubated for 3 days. To initiate the next selection cycle, the
transduced cells were detached from the membrane by
trypsinization and expanded for two days followed by cultiva-
tion in DMEM supplemented with 1 mg/ml G418 (Gibco,
Eggenstein, Germany) and 10% FCS for at least 5 days.
With each selection cycle, the co-cultivation periods within
the transwell system were decreased from 72 h (ﬁrst round
of selection) to 24 h (second round) and 12 h for the third
selection cycle.
For sequence analysis, vector particle RNA, or in most
cases, genomic DNA was isolated from transduced cells.
PCR was performed using Primers Seq2(+), 50-CCCCT-
ATTACTCCTCCTTCTGTTGCTCATCCTC-30 and GaLV-
R?( ), 50-CGATAAGCTTGATATCGAATTCTT-30,o r
Neo( ), 50-GGCGAACAGTTCGGCTGG-30. The resulting
PCR products were sub-cloned using the pGEM-TEasy kit
(Promega, Mannheim, Germany) and plasmid DNA from sin-
gle bacterial clones was sequenced using a standard T7 primer
(MWG, Ebersberg, Germany).
Fluorescence-activated cell sorting (FACS)
For FACS analysis 5 · 10
5 transfected cells were washed with
PBA [phosphate-bufferedsaline (PBS) with 2% FCSand 0.1%
sodium azide] and incubated with a-HA antibodies (Sigma,
Deisenhofen, Germany) in a 1:200 dilution for 45 min at 4 C.
After washing with PBA, cells were incubated with 1:50
diluted phycoerythrin (PE)-labeled secondary antibodies
directed against mouse IgG (Sigma, Deisenhofen, Germany)
for 30 min. After washing, cells were ﬁxed in PBS/1%
e41 Nucleic Acids Research, 2006, Vol. 34, No. 5 PAGE 2 OF 9paraformaldehyde and subjected to FACS analysis (FACScan,
Becton Dickinson, San Jose, USA).
Western blot analysis
Cells were harvested 48 h after transfection and lysed in RIPA
lysis buffer [25 mM Tris (pH 8), 137 mM NaCl, 10% glycerol,
0.1% SDS, 0.5% NaDOC, 1% NP40, 2 mM EDTA]. Upon
immunoprecipitation using the monoclonal a-HA antibody
(Sigma, Deisenhofen, Germany), TM protein was detected
by western blot analysis using hybridoma supernatants con-
taining the rat monoclonal antibody 42/114 10 at a 1:12.5
dilution (11). Anti-rat IgG (rabbit; DAKO, Glostrup, Den-
mark) horseradish peroxidase (HRP) conjugate was used as
secondary antibody in a 1:2000 dilution. Detected proteins
were visualized using the SuperSignal chemoluminescence
kit (Pierce, Rockford, USA).
Quantitative cell-to-cell fusion assays
Measurement of Env protein-mediated syncytia formation was
performed as described elsewhere (13). In brief, 5 · 10
5
murine NIH-3T3 cells were transfected with pCMV-a,
encoding the a-subunit of b-galactosidase, and the corre-
sponding pMSCV-GaLV expression plasmid (1.5 mg,
each). In parallel, the same number of HEK-293T target
cells was transfected with 3 mg of pCMV-w, expressing the
w-subunit of b-galactosidase. Two days post transfection, the
cells were harvested and  2.5 · 10
5 cells of each type were
mixed and incubated in thin-walled PCR tubes at 37 C for the
desired time period. Subsequently, cells were lysed in 100 ml
lysis buffer [100 mM potassium phosphate (pH 7.8), 0.2%
Triton X-100] and 10 ml of this solution were used for
luminescent measurement of b-galactosidase activity using
GalactoStar reagents (Applied Biosystems) and a microplate
luminometer.
RESULTS
Establishing Fusoselect
The key element of Fusoselect (Figure 1A) is the coupling of
cell–cell fusion with the release of retroviral vector particles
that speciﬁcally package and transfer genes encoding fusion-
competent membrane proteins. For selection a retroviral
packagable library encoding fusion donor protein variants is
expressed in a suitable cell type (donor cell) and co-cultivated
with a retroviral packaging cell line expressing the respective
fusion acceptor protein (acceptor packaging cell). The expres-
sion of a fusion-competent library member in a given donor
cell facilitates fusion with a neighboring acceptor packaging
cell which produces retroviral particles able to package and
transfer genetic information linked to a retroviral packaging
signal. Upon cell-to-cell fusion, the resulting syncytium
releases retroviral vector particles that have packaged the cod-
ing sequence of the fusion-competent donor protein variant.
Cells transduced with these particles can be used to amplify
the selected genes and to initiate the next selection cycle by
repeating co-cultivation with acceptor packaging cells.
Toestablishthissystemwechosethe GaLVEnvproteinand
its receptor (GLVR1) as fusion donor/acceptor pair (14) and
performed a model selection (Figure 2). In particular, we
assayed the selective pressure by applying the procedure to
a mixture of plasmids encoding the fusion-competent mutant
EnvDR and the fusion-incompetent wild-type (wt) Env (15).
To avoid fusion among the donor cells expressing the DR
variant, the GLVR1-negative (GLVR1 ) murine cell line
NIH-3T3 was used for expression. As acceptor cells we
used the GLVR1-positive (GLVR+) Phoenix-Eco cell line
which releases ‘empty’ (no transfer vector packaged) MLV
particles displaying the ecotropic MLV Env protein (www.
stanford.edu/group/nolan/retroviral_systems/retsys.html). The
coding sequences for both GaLV Env variants were provided
by the retroviral transfer vector plasmid pMSCV-GaLV (10)
(Figure 1B). To start the selection, retroviral vector particles
were generated having packaged the corresponding genes at
a ratio of 20:1 (wt/DR) and were used to transduce murine
NIH-3T3 cells at a multiplicity of infection (MOI) of <1.
Transduced cells expressing a single copy of the genes
were subsequently co-cultivated with Phoenix-Eco cells
according to the Fusoselect procedure. Cell-free supernatants
harvested after each selection cycle were used to purify viral
vector RNA subsequently serving as a template for RT–PCR
to determine the ratio ofthe packaged genes.Prior to selection,
a strong signal corresponding to the non-fusogenic wt Env was
obtained whereas the signal corresponding to the fusogenic
variant DR appeared much weaker (Figure 2, lane 2), thus
being in good agreement with the initial 20:1 ratio. With
ongoing selection cycles, the wt GaLV Env-derived signal
decreased and disappeared completely during the second
selection cycle (Figure 2, lanes 2–5). In contrast, the
EnvDR-derived signal persisted over all three selection cycles
performed. Thus, proof of principle for Fusoselect was
obtained.
Selection of fusion-active variants of retroviral
Env proteins
To demonstrate the utility of Fusoselect, we addressed the
question if Env variants can be selected that are fusion-
competent in absence of the viral protease. Amino acid resi-
dues K618, I619 and R623, all located within the R peptide
cleavage site, were diversiﬁed by insertion of randomized
oligonucleotides into the C-tail of GaLV env (11). Two
types of plasmid libraries, pMSCV-GaLV-X3 and pMSCV-
GaLV-X3-NEO, differing in the presence or absence of a
neomycin resistance gene were generated (Figure 1B). Prior
to selection, the plasmid libraries were transfected into viral
packaging cells thereby generating VSV-G pseudotyped MLV
vector particles. These were then used to transduce the pack-
aged libraries into murine NIH-3T3 cells, thus becoming
potential fusion donor cells. Subsequently, the selection pro-
cedure was initiated. Vector particles released from the co-
cultures with Phoenix-Eco cells were incubated with NIH-3T3
cells. These transduced cells were either used to prepare
genomic DNA for sequence analysis of any selected variants
or, in case of the pMSCV-GaLV-X3-NEO library, selectively
ampliﬁed by expansion in G418-supplemented media. The
G418-resistant cells were then used as fusion donor cells to
initiate another selection cycle. In this setting, the selective
pressure on fusion competence was increased with each selec-
tion cycle by decreasing the time of co-cultivation and thus the
time period allowed to complete cell–cell fusion.
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library nine independent clones were obtained showing a high
rate of amino acid alterations in addition to the diversiﬁed
residues (data not shown; Table 1). Yet, about 30% of
these clones were found to be fusion-competent (data not
shown). However, the selection procedure including G418
selection of the transduced cells was even more efﬁcient.
After three rounds of selection almost 100% fusion-
competent variants were obtained (see below). To monitor
the progress of the selection G418-resistant bulk populations
of transduced NIH-3T3 cells from each selection cycle were
co-cultivated with GLVR+ HEK-293T cells. Subsequently,
syncytia formation was determined using light-microscopy
(Figure 3). NIH-3T3 cells expressing the unselected library
did not form any visible syncytia. In contrast, NIH-3T3 cells
recovered from all other selection cycles induced the forma-
tion of multinucleated cells. Furthermore, the number of
nuclei within each syncytium increased from approximately
seven after the ﬁrst selection round to about 15 after the third
selection round. This also correlated with an increased number
of syncytia within the culture ﬂask from only a few to several
thousands (data not shown). Sequence analysis of the selected
clones revealed the obvious accumulation of distinct motifs.
Clone #1 appeared most prevalently represented by 17 out of
34 clones analyzed. Surprisingly, it contained further muta-
tions in addition to the diversiﬁed positions. Consequently,
amino acid residues 617 to 626 differed from the parental
Env protein (Table 1). Noteworthy, these mutations could
not have resulted from simple frameshifts but most likely
originated from recombination events during reverse tran-
scription of the vector particle packaged RNA. Clone #48
was obtained through the selection of both libraries (once
from pMSCV-GaLV-X3 and twice from pMSCV-GaLV-
X3-NEO). Strikingly, this clone contains an insertion of an
additional nucleotide resulting in the deletion of the R peptide.
Nevertheless, sequences that differed from the parental Env
exclusively at the diversiﬁed residues were also selected.
(Table 1, clones #7 and #12).
A
B
Figure1.Experimentaldesign.(A)PrincipleofFusoselect.Fusiondonorcells(grey)expressingactive(filledtriangle)orinactive(filledsquare)fusiondonorprotein
variantsfromaretroviral(MLV)packagabletransfervector(shownasdoublehelices)areco-cultivatedwithanacceptorpackagingcell(white)expressingthefusion
acceptor, the retroviral (MLV) Gag/Pol proteins (hexagons) and the Env protein of the ecotropic MoMLV (lollipops) in the bottom chamber of a transwell system.
Afusion-competentdonorvariantwillmediatecell–cellfusion.Thus,uponsyncytiaformation,thevectorencodingthefusion-competentdonorvariant(brighthelix)
is packaged into vector particles and will be transferred into fusion acceptor-negative target cells (dotted) seeded on to the membrane of the top transwell chamber.
Thecodingsequenceforfusion-activedonorvariantscanberescueddirectlyfromthetargetcellsoruponamplificationfollowingG418selection(incasethetransfer
vectorconfersresistance).Notethatfusionproteinvariantsthatmightbecomeincorporatedintothereleasedparticles(datanotshown)donotaffectthetransduction
efficiency of the target cells since the corresponding fusion acceptor protein is not expressed. (B) Schematic representation of the plasmids used. The MLV-
packagablepMSCVvectorencodestheHA-taggedGaLVEnvproteinundercontrolofthe50-LTR.TheplasmidpMSCV-ClontechfeaturesanadditionalNeomycin
resistancecassette(Neo
R)drivenbyamurinephosphoglyceratekinasepromoter(pPKG).ThediversifiedaminoacidresiduesoftheX3-librariesaredepictedinbold.
e41 Nucleic Acids Research, 2006, Vol. 34, No. 5 PAGE 4 OF 9Characterization of the selected Env variants
Selected variants from both libraries were re-inserted into the
pMSCV-GaLV-WT backbone to exclude an inﬂuence of any
possible mutations outside the sequenced part of the selected
env genes on the phenotype. The resulting constructs and the
wt- and DR-encoding plasmids were then transfected into
HEK-293T cells to allow comprehensive characterization of
the selected variants. First, the expression rates were deter-
minedbystainingthetransfectedcells withantibodiesdirected
against the HA epitope and subsequent FACS analysis
(Figure 4A). All constructs, including the wt Env, showed
similar signal intensities revealing highly efﬁcient surface
expression. In parallel, the transfected cells were analyzed
by microscopy for cell-to-cell fusion. While the wt Env did
not mediate any detectable syncytia formation, expression of
the DR-mutant and the selected variants resulted in the forma-
tion of syncytia with up to 25 nuclei (Figure 4B). Next, the
cell–cell fusion-activity of the selected variants was quantiﬁed
using a fusion assay in which syncytia formation results in
b-galactosidase activity (13). The wt Env protein was negative
in this assay resulting in comparable values as Env-negative
control cells. Allowing only 5 h for cell-to-cell fusion of NIH-
3T3 cells expressing the selected variants and the GLVR+
HEK-293T cells, all selected variants showed fusion-
activities which were at least two orders of magnitude higher
than the background level (Figure 5A). After co-cultivation for
22 h the signals of all variants increased further by more than
one order of magnitude without signiﬁcant changes in the
relative signal intensities (Figure 5A). Thus, the selected vari-
ants mediated cell-to-cell fusion as efﬁcient as the DR positive
control while the parental wt Env showed signiﬁcantly less
activity.
Since cell entry of retroviruses is based on membrane
fusion, variants surviving this selection procedure should
mediate virus–cell fusion. To prove this, we generated
MLV and HIV vector particles displaying the selected Env
protein variants, respectively. While the MLV protease is able
to cleave off the GaLV-R peptide, the HIV protease is not
(11,15). Therefore, infectious HIV vector particles cannot be
formed with the parental Env protein. However, as all the
selected variants developed R peptide inactivation we antici-
pated also the formation of infectious HIV vector particles. In
context of MLV particles, the fusion-active variants #1, #12
and #27 mediated on average 5-fold higher titers than the
parentalEnvprotein (data notshown).However,HIVparticles
pseudotyped with the ﬁve variants tested exerted at least low
infectivity (>10
2 U/ml). Remarkably, employing Env variants
#7 and #27 for HIV vector generation resulted in much higher
Figure 2. Selection of a model library. A mixture of NIH-3T3 cells expressing
thenon-fusogenicwtEnvorthefusogenicEnvDRinaratioof20:1wasapplied
to the selection procedure. Particles from each selection cycle (S0–S3) were
usedforRT–PCRofthepackagedgenes.Primersweredesignedtoresultintwo
different PCR fragments for the wt and the DR Env (indicated with arrows).
Table 1. Selected variants from the GaLV-X3 libraries
a
Clone Selected sequence
b Library
c Frequency
#
WT RISAV K I LVL R QKYQALENEGNL control control
#1 RISAG CSTGP C AEIQALENEGNL- n 17/34
#7 RISAV RKLVL D QKYQALENEGNL- n 1/34
#48 RISAV PGLGP S PEISGSRERR- m and n 1/9 and 2/34
#12 RISAV RRLVL P QKYQALENEGNL- m 1/9
#27 RISAV R L LGP- m 1/9
aOnly those variants that were used for further analysis are listed.
bDiversifiedpositionsaredepictedinbold,additionalmutationsareunderlined,
the R peptide cleavage site is indicated by an arrow.
cClones obtained from selection of the pMSCV-GaLV-X3-NEO library (n) or
pMSCV-GaLV-X3 library (m).
Figure 3. Increasing fusogenicity of selected variants during selection of the
pMSCV-Clontech-X3 library. Transduced NIH-3T3 cells from each selection
cycle were co-cultivated withGLVR1
+ HEK-293Tcells. The stringencyof the
selection was increased with ongoing cycles by decreasing the time available
for cell-to-cell fusion. Syncytia formation was analyzed under the light-
microscope at 200-fold magnification. Multinucleated cells are labeled by
white lines.
PAGE 5 OF 9 Nucleic Acids Research, 2006, Vol. 34, No. 5 e41Figure 4. Characterization of selected variants. (A) Surface expression of selected variants on transfected HEK-293T cells determined by FACS analysis using
anti-HA antibodies. Untransfected cells served as control. (B) Syncytia formation of transfected HEK-293T cells mediated by selected variants or controls.
Multinucleatedcellswereobservedunderthelight-microscopeatdifferentmagnifications(leftcolumn¼200-fold,rightcolumn¼100-fold).Syncytiaareframedin
white lines.
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5U/ml) suggesting their applicabilityforHIV vector
production.
Since no viral protease capable of cleaving the R peptide
was expressed in the fusion donor cells during selection, we
tested if the newly evolved variants were processed by a cel-
lular protease. For this purpose, plasmids encoding the
selected variants or controls were transfected into
HEK-293T cells. Two days post transfection cell lysates
were prepared and subsequently subjected to a combined
immunoprecipitation and western blot analysis using TM
protein-speciﬁc antibodies. While only the background signal
derived from the light chain of the antibody used for the
immunoprecipitation step was detectable in the negative con-
trol sample, distinct bands were obtained for the different
variants (Figure 5B). As expected, the TM protein of the
parental Env migrated as a single band at  15 kDa, whereas
a band corresponding to a lower molecular mass was obtained
for the EnvDR variant (lanes 2 and 3). Clones #1, #7 and #12
migrated as single bands at the same position as the parental
TM protein. Thus, there was no evidence for further process-
ing of these variants, while the parental Env was cleaved when
coexpressed with the viral protease (compare lanes 4–6 with
lane 1). Clone #27 showed a band at a lower molecular weight
resulting from the deletion of the R peptide. This variant
encodes only two more amino acids than the TM protein of
the EnvDR variant (lane 7). Clone #48 revealed an
electrophoretic mobility between that of the parental TM and
that ofthe EnvDRvariant probably duetoits uniquelengthand
three additional positively charged arginine residues (lane 8).
Overall these results demonstrated that the selected variants
did notrequire any further processing to become fusion-active.
The latter is especially remarkable for clones #7 and #12 since
these variants encompassed the complete R peptide.
DISCUSSION
We report here a novel directed evolution strategy, termed
‘Fusoselect’ allowing for comprehensive analysis and engi-
neering of cell–cell fusion-activity within TMs. The system is
based on coupling cell-to-cell fusion, mediated by a fusion-
active protein variant, with the release of retroviral particles
that have packaged the coding region of the respective protein.
This strategy was instrumental to set up an in vivo system that
selects for the formation of lethal syncytia, i.e. a cytotoxic
property. This has so far only been possible via the generation
of replica-libraries and the screening of small library pool
fractions, as described for the identiﬁcation of the HIV co-
receptor (16,17). However, replica-libraries only allow low
diversities and require time consuming sub-fractionation
steps. Due to its integrated signal ampliﬁcation Fusoselect
circumvents these limitations. The selected genes can easily
be ampliﬁed, expressed and analyzed upon transduction of
fusion acceptor-negative indicator cells with the released
vector particles.
Since the determinants for membrane fusion activation are
well characterized for Env proteins of retroviruses, we used
these to demonstrate the power of Fusoselect by showing that
fusion-inactive Env proteins can be converted to fusion-active
ones. Even without ampliﬁcation of the packaged genes,
fusion-active variants were obtained from libraries of Env
proteins, diversiﬁed at three amino acid residues located in
their CTs, after just one round of selection. By employing
retroviral transfer vectors that encoded an additional antibiotic
resistance gene several selection rounds could be performed.
Thereby, an additional level of diversiﬁcation mediated by the
reverse transcription process was introduced. In fact, most of
the selected variants carried such mutations (see below). After
three selection rounds all of the characterized clones were
fusion-competent revealing the high stringency of the selec-
tion procedure.
The selected variants not only gained cell–cell fusion com-
petence but were also active in mediating cell entry of retro-
viral and lentiviral vector particles. This clearly shows the
potential of Fusoselect in optimizing gene transfer systems
e.g. for gene therapy purposes.
A more detailed look at the selected Env protein variants
revealed how fusogenicity has been evolved. The most fre-
quently selected clone #1 had accumulated several glycine and
Figure 5. (A) Quantitative cell-to-cell fusion assay. NIH-3T3 cells transfected
with pCMV-a and the corresponding pMSCV-GaLV construct were mixed
with an equal number of HEK-293T target cells expressing pCMV-w and
incubated at 37 C for either 5 h (dark bars) or 22 h (bright bars). Subsequently,
b-galactosidase activity in cell lysates was determined using a luminometric
assay. (B) R peptide cleavage of selected variants and controls. Cell lysates of
transfected HEK-293T cells were subjected to immunoprecipitation with an
anti-HA antibody followed by western blot analysis using anti-TM antibodies.
Untransfectedcellsservedasanegativecontrol(lane9).Aspositivecontrolfor
R peptide cleavage, purified MLV particles having the wild-type GaLV Env
incorporatedwere loadedin lane 1. The positionsof the unprocessed (TM) and
processed (TM-DR) form of the TM protein are indicated. The light chains of
the anti-HA antibody used for immunoprecipitation are labeled by an asterisk.
Arrows point to the positions of the selected TM protein variants.
PAGE 7 OF 9 Nucleic Acids Research, 2006, Vol. 34, No. 5 e41serine residues. Previous investigations of the MLV Env pro-
tein revealed that fusion-activity can be achieved in the
absence of R peptide cleavage by introduction of glycine
and serine residues upstream of the R peptide, most likely
rendering the CT more ﬂexible and releasing the inhibitory
constraint (18). Our results indicate that this is a general
mechanism of g-retroviral Env proteins. Another way to
gain fusion-activity is either by truncation or by complete
exchange of the R peptide as seen for selected clones #27
and #48. Interestingly, variants that differed from the parental
fusion-inactive protein within the diversiﬁed sites only were
also selected. These variants (clone #7 and #12) had positively
charged amino acids at residues 618 and 619 in common. As R
peptide cleavage and improved cell surface trafﬁcking could
be excluded for these variants, altered folding of the C-tail due
to the additional charges resulting in a non-functional R pep-
tide appears to be the most likely explanation. Taken together,
the selected variants gained fusion-activity either by trunca-
tion, deletion or altered folding of the R peptide but not by
proteolytical cleavage through cellular proteases. This might
be due to the fact that only three residues of the viral cleavage
site were diversiﬁed initially, making the generation of motifs
that are recognized by cellular proteases rather unlikely.
An immediate application of Fusoselect will be the evolu-
tion of highly speciﬁc suicide genes for cancer gene therapy. It
has been shown previously that fusogenic envelope proteins
exhibit a strong bystander effect facilitating cell death of
tumor cells at high efﬁciency (19). These proteins can be
engineered, e.g. by fusion to scFvs or receptor ligands, to
mediate cell–cell fusion by binding to speciﬁc cell surface
markers acting as fusion acceptors (20,21). Fusoselect will
allow thescreeningofhighlydiverse librariesofsuchmodiﬁed
envelope proteins. Alternatively, targeted cell–cell fusion-
activity might be achieved by evolving speciﬁc cleavage
sites within the TM cytoplasmic domain forcalpain, a protease
known to be overexpressed in a variety of cancer cells (22,23).
Beyond that, we expect Fusoselect to become applicable for
proteins involved in cellular membrane fusion events as well,
since there is no requirement for the protein of interest to be of
viral origin or to become incorporated into the retroviral par-
ticles. The selection of variants not covered by the library
design as shown here for variants #1 and #48 shows that
veryraresingleevents, occurring through reverse transcription
during the screening procedure, within the library can be iden-
tiﬁed by Fusoselect. The scale up of Fusoselect required for
this purpose should be easily achievable. Plenty examples
exist demonstrating that retroviral cDNA libraries covering
complexities greater than 1 · 10
6 can be successfully gener-
ated and screened on a single cell level (24,25). Then, yet
unknown proteins mediating cell–cell fusion directly, such
as fusion-active envelope proteins originating from endoge-
nous retroviruses and their cognate receptors (26,27), or indi-
rectly, such as proteins involved in vesicle fusion (28,29)
could be identiﬁed by subjecting retroviral cDNA libraries
to the Fusoselect screening procedure.
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